Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study

Archives of Internal Medicine

Volumn 159, Issue 2, 1999, Pages 161-166

  Smalley, Walter ^a,b,c   Ray, Wayne A ^b   Daugherty, James ^b   Griffin, Marie R ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; SULINDAC; TOLMETIN; ZOMEPIRAC;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MEDICAID; RETROSPECTIVE STUDIES; TENNESSEE; UNITED STATES;

EID: 0033601773     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.2.161     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;65:5-27.
2. Woolf SH. Screening for colorectal cancer. In: DiGuiseppi C, Atkins D, Woolf SH, Kamerow DB, eds. US Preventive Services Task Force: Guide to Clinical Preventive Services. Alexandria, Va: International Medical Publishing: 1996:89-103.
3. Screening for colorectal cancer: United States, 1992-1993, and new guideliens. MMWR Morb Mortal Wkly Rep. 1996;45:107-110.
4. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399-4404.
5. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83:355-358.
6. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72:1171-1177.
7. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994;154:394-399.
8. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer. 1994;74:1847-1854.
9. Thun MJ, Namboodiri MM. Health CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
10. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
11. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-246.
12. Giovannucci E, Egan KM, Hunter DJ, et al. Asprin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-614.
13. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci. 1996;41:1319-1326.
14. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996:5:955-960.
15. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993: 328:1313-1316.
16. Berkel HJ, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Epidemiol Rev. 1996;18:205-217.
17. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract. Rev Gastroenterol. 1995;109:285-301.
18. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcmomas. Gastroenterology. 1994;107:1183-1188.
19. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993; 85:1220-1224.
20. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109:359-363.
21. Smalley WE, Ray WA, Daugherty J, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995:141:539-545.
22. Smalley WE, Griffin MR. Fought RL, Ray WA. Excess costs for gastrointestinal disease among nonsteroidal anti-inflammatory drug users. J Gen Intern Med. 1996:11:461-469.
23. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and risk of chronic renal disease. Ann Intern Med. 1991;115:165-172.
24. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med. 1990;112:568-576.
25. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129:837-849.
26. Physicians' Desk Reference. 48th ed. Montvale. NJ: Medical Economics Data Production Co; 1994.
27. World Health Organization. International Classification of Diseases, Ninth Revision. Clinical Modification (ICD-9). Geneva. Switzerland: World Health Organization; 1977.
28. Colon and rectum. In: American Joint Committee on Cancer, ed. AJCC Cancer Staging Manual. New York. NY: Lippincott-Raven; 1997:83-89.
29. SAS Institute Inc. SAS Users Guide: Statistics. Cary, NC: SAS Institute Inc: 1985.
30. Dobson A, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10:457-462.
31. SAS Institute Inc. SAS/STAT Software: the GENMOD Procedure, Release 6.09. Cary, NC: SAS Institute Inc; 1993. SAS Technical Report P-243.
32. Thun MJ, Namboodiri MM, Calle EE, Heath CW Jr. Asprin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
33. Negri E, Braga C, La Vecchia C, et al. Family history of cancer and risk of colorectal cancer in Italy. Br J Cancer. 1998;77:174-179.
34. Senba S, Konishi F, Okamoto T, et al. Clinicopathologic and genetic features of nonfamilial colorectal carcinomas with DNA replication errors. Cancer. 1998;82: 279-285.
35. Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Dig Dis. 1997;15:302-311.
36. Liu T. Mokuolu AO, Rao CV, Reddy BS, Holt PR. Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology. 1995;109: 1167-1172.
37. Jacoby RF. Marshall DJ. Newton MA. et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996;56:710-714.
38. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co: 1986.
39. Gabriel SE, Jaakkimainen L, Bombardier C. Risktor serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a metaanalysis. Ann Intern Med. 1991;115:787-796.
40. Physician's Health Study Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;318: 262-264.
41. Kelloff GJ, Boone CW, Sigman CC, Greenwald P. Chemoprevention of colorectal cancer. In: Young GP. Rozen P, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. Philadelphia, Pa: WB Saunders Co: 1996:115-139.
42. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. In: DuBois RN, Giardiello FM, eds. Gastroenterology Clinics of North America. Philadelphia. Pa: WB Saunders Co; 1996:363-372.